# Remlifanserin PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/remlifanserin

> Remlifanserin, sponsored by ACADIA PHARMACEUTICALS INC (ACAD): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | remlifanserin |
| Codes | ACP-204 |
| Sponsor | ACADIA PHARMACEUTICALS INC (ACAD) https://sec-api.dev/companies/acad/catalysts |
| Indications | hallucinations and delusions associated with adp |
| Modality |  |
| FDA designations | fast track |

## Timeline

### Nov 2023: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: hallucinations and delusions associated with ADP.
- First seen 2025-02-27, last confirmed 2026-02-26.
- SEC Form 10-K (accession 0001193125-26-072519): "In November 2023, we initiated a Phase 2 study evaluating the efficacy and safety of remlifanserin for the treatment of hallucinations and delusions associated with ADP." https://www.sec.gov/Archives/edgar/data/1070494/000119312526072519/acad-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-267453): "In November 2023, we initiated a Phase 2 study evaluating the efficacy and safety of ACP-204 for the treatment of hallucinations and delusions associated with ADP." https://www.sec.gov/Archives/edgar/data/1070494/000119312525267453/acad-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-104295): "In November 2023, we initiated a Phase 2 study evaluating the efficacy and safety of ACP-204 for the treatment of hallucinations and delusions associated with ADP." https://www.sec.gov/Archives/edgar/data/1070494/000095017025104295/acad-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-066231): "In November 2023, we initiated a Phase 2 study evaluating the efficacy and safety of ACP-204 for the treatment of hallucinations and delusions associated with ADP." https://www.sec.gov/Archives/edgar/data/1070494/000095017025066231/acad-20250331.htm
- SEC Form 10-K (accession 0000950170-25-029253): "In November 2023, we initiated a Phase 2 study evaluating the efficacy and safety of ACP-204 for the treatment of hallucinations and delusions associated with ADP." https://www.sec.gov/Archives/edgar/data/1070494/000095017025029253/acad-20241231.htm

### Q3 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-02-26, last confirmed 2025-08-07.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-027759): "In January, the Company announced plans for the initiation of a Phase 2 study of ACP-204 for a second indication in Lewy Body Dementia Psychosis in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1070494/000095017025027759/acad-ex99_1.htm
- SEC Form 10-Q (accession 0000950170-25-104295): "We plan to initiate an additional Phase 2 study of ACP-204 in Lewy Body Dementia with Psychosis (LBDP) in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1070494/000095017025104295/acad-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-066231): "We plan to initiate an additional Phase 2 study of ACP-204 in Lewy Body Dementia with Psychosis (LBDP) in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1070494/000095017025066231/acad-20250331.htm
- SEC Form 10-K (accession 0000950170-25-029253): "We plan to initiate an additional Phase 2 study of ACP-204 in Lewy Body Dementia with Psychosis (LBDP) in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1070494/000095017025029253/acad-20241231.htm
- SEC Form 10-K (accession 0000950170-25-029253): "We plan to initiate an additional Phase 2 study of ACP-204 in LBDP in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1070494/000095017025029253/acad-20241231.htm

### Oct 2026: topline data readout

- Status: scheduled. Date confidence: month. Stage: 2.
- First seen 2025-02-26, last confirmed 2026-08-04.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-332858): "- Topline results from the Phase 2 remlifanserin study in Alzheimer's disease psychosis anticipated September to October 2026" https://www.sec.gov/Archives/edgar/data/1070494/000119312526332858/acad-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-332858): "Completed enrollment in the Phase 2 portion of the RADIANT program evaluating remlifanserin in Alzheimer's disease psychosis and initiated Phase 3 screening and enrollment; topline Phase 2 results are expected in September to October 2026." https://www.sec.gov/Archives/edgar/data/1070494/000119312526332858/acad-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-027759): "For the RADIANT Phase 2 study of ACP-204 in Alzheimer's disease psychosis, the last patient is expected to be enrolled in the first quarter of 2026, followed by topline results announcement in mid-2026." https://www.sec.gov/Archives/edgar/data/1070494/000095017025027759/acad-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-209253): "Phase 2 topline results readout from the remlifanserin Alzheimer's disease psychosis study remains on track for August to October 2026 timeframe." https://www.sec.gov/Archives/edgar/data/1070494/000119312526209253/acad-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-209253): "- Reaffirms expectation for topline results from the Phase 2 remlifanserin study in Alzheimer's disease psychosis between August and October 2026" https://www.sec.gov/Archives/edgar/data/1070494/000119312526209253/acad-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-197957): "After her retirement, Acadia plans to retain Dr. Thompson as a consultant through at least the end of 2026 to ensure scientific and leadership continuity through the planned readout of the Phase 2 clinical study of remlifanserin in Alzheimer's disease psychosis (ADP) and into early Phase 3 clinical study execution." https://www.sec.gov/Archives/edgar/data/1070494/000119312526197957/acad-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-071674): "We continue to advance a deep and differentiated R&D pipeline, anchored by remlifanserin, with the Phase 2 RADIANT study in Alzheimer's disease psychosis serving as an important upcoming potential catalyst with top-line results expected between August and October 2026."" https://www.sec.gov/Archives/edgar/data/1070494/000119312526071674/acad-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-071674): "Phase 2 top-line results readout from the remlifanserin Alzheimer's disease psychosis study remains on track for August to October 2026 timeframe, representing a potential catalyst for the Company this year." https://www.sec.gov/Archives/edgar/data/1070494/000119312526071674/acad-ex99_1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/remlifanserin.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Remlifanserin PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/remlifanserin

```bibtex
@misc{secapidev_pdufa_remlifanserin_20261116,
  title        = {Remlifanserin PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/remlifanserin}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_remlifanserin_20261116","title":"Remlifanserin PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/remlifanserin","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
